Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.54 |
| ▸ | HTR2B | P41595 | 9/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15566274 | 0.87 | HTR1A (0.55) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| Tert-Butyl Formate SCHEMBL28101025 | 0.86 | HTR2C (0.46) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2298746 | 0.83 | SLC6A4 (0.58) | HTR2CHTR2BSLC6A4 | |
| SCHEMBL5372606 | 0.83 | HTR2C (0.55) | HTR2CHTR2BSLC6A4SLC6A2HTR1A | |
| SCHEMBL941030 | 0.83 | SLC6A2 (0.58) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL2778482 | 0.82 | SLC6A2 (0.56) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL10276355 | 0.82 | HTR2C (0.54) | HTR2CHTR2BSLC6A4SLC6A2HTR1A | |
| SCHEMBL15566745 | 0.81 | HTR1A (0.51) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL19244801 | 0.81 | HTR2C (0.52) | HTR2CHTR2BSLC6A4HTR6 | |
| SCHEMBL13419259 | 0.81 | SLC6A2 (0.52) | HTR2CHTR2BSLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190059-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-06-18 | — | — | US | disclosed |
| US-10544126-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-01-28 | — | — | US | disclosed |
| US-10273225-B2 | Pyrazines as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-30 | — | — | US | disclosed |
| US-20190084962-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-21 | — | — | US | disclosed |
| US-10167273-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-01 | — | — | US | disclosed |
| EP-3105216-B1 | PYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-10 | — | — | EP | disclosed |
| US-20180258073-A1 | PYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2018-09-13 | — | — | US | disclosed |
| US-10000468-B2 | Pyrazines as modulators of GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-2855449-B1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-9770452-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20070179297-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-7238811-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7179922-B2 | 4-Phenyloxypiperidionopiperidine compounds as antiinflammatory agents; autoimmune diseases; rheumatic diseases; cardiovascular disorders | ASTRAZENECA AB (SE) | 2007-02-20 | — | — | US | disclosed |
| EP-1404667-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1604982-A1 | INTERMEDIATES FOR THE PREPARATION OF PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| US-20050171092-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1274701-B1 | [1,4']-BIPIPERIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6903115-B2 | Bipiperidine compounds | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084962-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | HTR2C 289/4885HTR2B 408/4885SLC6A4 181/4885 |
| US-10000468-B2 | Pyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | HTR2C 435/4885HTR2B 518/4885SLC6A4 1094/4885 |
| US-20200190059-A1 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | PROKR1, GIPR, PROKR2 | HTR2C 289/4885HTR2B 408/4885SLC6A4 181/4885 |
| US-10273225-B2 | Pyrazines as modulators of GPR6 | GPR6, GPR65, GPR52 | HTR2C 435/4885HTR2B 518/4885SLC6A4 1094/4885 |
| US-10544126-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | HTR2C 289/4885HTR2B 408/4885SLC6A4 181/4885 |
| US-20050171092-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HTR2C 1618/4885HTR2B 1606/4885SLC6A4 3874/4885 |
| US-10167273-B2 | Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases | PROKR1, GIPR, PROKR2 | HTR2C 289/4885HTR2B 408/4885SLC6A4 181/4885 |
| US-20070179297-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HTR2C 1618/4885HTR2B 1606/4885SLC6A4 3874/4885 |
| US-20180258073-A1 | PYRAZINES MODULATORS OF GPR6 | GPR6, GPR65, GPR52 | HTR2C 438/4885HTR2B 461/4885SLC6A4 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.